The companies have begun the Collaboration with a joint pre-clinical study and are expecting its results potentially to deepen the Collaboration between the parties.
TORONTO, March 08, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0)
(“Clearmind” or the „Company„), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced a Collaboration agreement (the “Collaboration”) with SciSparc Ltd. (NASDAQ: SPRC).